佐力药业 (300181.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

11.3x

Market Cap

CNY 9.80B

MomentumView details →

1D Return

−1.20%

YTD Return

−16.77%

RSI (14)

39.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

11.3x

Market Cap

CNY 9.80B

RSI (14)

39.2

MomentumView details →

1D Return

−1.20%

YTD Return

−16.77%

ProfitabilityView details →

Gross Margin

62.43%

Net Margin

20.88%

EBITDA Margin

27.20%

ROE (TTM)

18.99%

ROA (TTM)

12.20%

Asset Turnover

0.62x

GrowthView details →

Revenue YoY

+14.10%

EPS YoY

+19.28%

FCF YoY

+412.52%

Revenue CAGR 3Y

+18.98%

EPS CAGR 3Y

+26.92%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.22x

Current Ratio

1.55x

Quick Ratio

1.21x

Div Yield

2.60%

Div Rate

CNY 0.35

Div Growth 1Y

−41.67%

Financials snapshotView financials →

Revenue (TTM)

3.11B

Net Income (TTM)

650.37M

Op. CF (TTM)

569.25M

Latest newsMore news →

Zhejiang Jolly Pharmaceutical announced a cash dividend of 3.5 yuan per 10 shares (tax inclusive) for the 2026 first half, with no capital reserve conversion to share capital.9d ago

Zhejiang Jolly Pharmaceutical disclosed its 2026 first-half results: revenue of 1.764 billion yuan, up 10.30% year-on-year; net profit attributable to shareholders of 375 million yuan, up 0.38% year-on-year; non-recurring-adjusted net profit of 374 million yuan, up 0.53% year-on-year.9d ago

Similar companies

豪恩汽电301488.SZ 天康生物002100.SZ 利安隆300596.SZ 冠捷科技000727.SZ 匠心家居301061.SZ 达利凯普301566.SZ Find similar companies →

Latest newsMore news →

Zhejiang Jolly Pharmaceutical announced a cash dividend of 3.5 yuan per 10 shares (tax inclusive) for the 2026 first half, with no capital reserve conversion to share capital.9d ago Zhejiang Jolly Pharmaceutical disclosed its 2026 first-half results: revenue of 1.764 billion yuan, up 10.30% year-on-year; net profit attributable to shareholders of 375 million yuan, up 0.38% year-on-year; non-recurring-adjusted net profit of 374 million yuan, up 0.53% year-on-year.9d ago